Beta Thalassemia Genetic Testing
Beta thalassemia is a predominately recessive inherited blood disorder characterized by a reduction in the synthesis of the β-globin chain. This leads to a relative excess of the α-globin chain. The clinical result is a hypochromic microcytic anemia and nucleated RBCs present in peripheral blood smear. Beta thalassemia is due to mutations in the HBB gene. Over 200 mutations of this gene have been documented. Most cases of beta thalassemia arise from single base pair changes associated with the beta globin gene on chromosome 11. Although rare, gene deletions have also been reported. When a mutation is present, there is a decrease in β-globin chain production, resulting in a relative excess of unbound α-globin chains. Excessive α-globin chains are unable to form a soluble tetramer and precipitate in erythroid precursor cells in the bone marrow. α-globin precipitation leads to premature cell death and ineffective erythropoiesis. With decreased production of the β-globin chain, there is compensatory increase in production of alternate globin chains, the type of amount depending on the severity of the HBB gene mutation. For example, in β0 thalassemia, there is 0% normal hemoglobin (Hb) A, 90-95% HbF and 2-5% HbA2 and in β+ thalassemia, there is 10- 30% HbA, 7-90% HbF and 2-5% HbA2. β-thalassemia minor carriers usually show 92- 95% HbA, 0.5-4% HbF and 3.5% HbA2. Three main mutation types of beta thalassemia exist:
Beta thalassemia major: homozygous form (Cooley’s anemia, Mediterranean anemia.)
- β◦ thalassemia major: complete absence of β chain synthesis
- β+ thalassemia major: incomplete suppression of β chain synthesis
Patients present with severe anemia during the first 2 years of life, requiring regular transfusions and chelation therapy.
Beta thalassemia intermedia: genetically heterozygous, variable degrees of severity
Beta thalassemia minor (trait): heterozygous form. Results in moderate, asymptomatic suppression of beta chain synthesis.
In rare cases, the mutation of the HBB gene is also associated with other hemoglobinopathy mutations. Examples include HbC/beta thalassemia, HbE/ beta thalassemia and HbS/beta thalassemia. Also in rare instances beta thalassemia is not associated with mutations of the HBB gene, but is instead the result of different mutations; for example, mutations in the gene encoding the transcription factor TFIIH are associated with beta thalassemia associated with tricothiodystrophy and xeroderma pigmentosum and mutations in the X-linked transcription factor GATA-1 are associated with X-linked thrombocytopenia with thalassemia. Differential diagnoses to consider include: sideroblastic anemias, congenital dyserythropoietic anemia, juvenile myelomonocytic leukemia, and aplastic anemia. Currently, the only cure for β-thalassemia is bone marrow transplantation.
- Carrier screening individuals and their reproductive partners with a family history of β-thalassemia
- Newborn screening to facilitate reduction in thalassemia related morbidity
- Diagnosis of β-thalassemia or other β-hemoglobinopathy
- Confirmation of a specific β-globin mutation in parents prior to prenatal diagnosis
Negative for mutation analyzed (No mutation detected)
EDTA Whole blood, blood spots, cultured fibroblasts, cultured amniocytes or chorionic villi, extracted DNA from skin biopsy, buccal or salivary sample. Do not freeze samples.
Stability
- Refrigerated: 7-14 days
- Hematol Rep. 2012 May 10;4(2):e9. [PMID: 22826799]
- J Pharm Bioallied Sci. 2012 Jul;4(3):194-201. [PMID: 22923960]
- Orphanet J Rare Dis. 2010 May 21;5:11. [PMID: 20492708]
- Genet Med. 2010 Feb;12(2):61-76. [PMID: 20098328]
- Haematologica. 2005 May;90(5):649-60. [PMID: 15921380]
- Thalassemia. Mediterranean anemia, Cooley’s anemia, Beta thalassemia, Alpha thalassemia. Atlanta, GA. A.D.A.M Medical Encyclopedia, U.S. National Library of Medicine (2012).